Histrelin
Histrelin acetate, SPD424
Histrelin is a synthetic nonapeptide GnRH agonist delivered exclusively as a small flexible implant inserted under the skin of the inner upper arm, which releases drug steadily for a full year. Its principal use is central precocious puberty in children, where replacing monthly injections with a single annual procedure is a substantial practical advantage. The implant is non-biodegradable and must be removed and, if treatment continues, replaced.
Mechanism
Histrelin substitutes N-benzyl-D-histidine for glycine at position 6 of native GnRH and replaces the C-terminal glycinamide with an ethylamide. The benzylated D-histidine is a bulky, aromatic, non-natural residue that blocks the proteolytic cleavage terminating native GnRH signalling while markedly increasing GnRH receptor affinity, making histrelin one of the more potent agonists in the class. The ethylamide C-terminus adds further resistance to carboxypeptidase degradation.
What distinguishes histrelin clinically is not its pharmacology but its delivery. The drug is dispersed in a non-biodegradable hydroxypropyl methacrylate hydrogel cylinder implanted subdermally. The hydrogel hydrates in tissue and releases histrelin by diffusion at a near-constant rate for approximately 12 months, producing genuinely continuous receptor exposure rather than the sawtooth profile of repeated depot injections. That continuity is mechanistically ideal for the intended effect: uninterrupted GnRH receptor occupancy drives receptor downregulation and gonadotroph desensitisation, collapsing LH and FSH secretion and returning sex steroid concentrations to prepubertal levels. In central precocious puberty this halts breast or testicular development, arrests the accelerated bone age advancement that would otherwise cause premature epiphyseal fusion, and preserves adult height potential. Because the implant is not biodegradable, it must be surgically removed at the end of its life.
What the research shows
The pivotal multicentre trial enrolled 36 children with central precocious puberty and implanted a single histrelin device. Suppression was rapid and near-universal: by one month, peak stimulated LH and oestradiol concentrations were significantly suppressed, and hormonal suppression was maintained throughout the 12-month study period. Growth velocity slowed towards prepubertal norms and the rate of bone age advancement decreased, both of which are the mechanistically expected consequences and the endpoints that matter for eventual adult height. Local implant-site reactions were the most common adverse events, and implant removal occasionally proved difficult because of fibrous encapsulation. It should be stated plainly that this was a single-arm open-label study with no control group.
A subsequent independent study addressed a question the registration trial could not: whether the implant's effect outlasts its nominal one-year life. Investigators found that a single histrelin implant maintained effective pubertal suppression for two years, raising the reasonable possibility that annual replacement is more frequent than strictly necessary in some children. This is a genuinely useful finding, since each replacement means another minor surgical procedure in a child, but it comes from a limited observational cohort rather than a randomised comparison of one-year versus two-year replacement intervals, so it has not displaced the licensed schedule. The broader limitation across all GnRH agonist trials in precocious puberty is that final adult height, the outcome families actually care about, requires a decade or more of follow-up, so most trials report surrogate endpoints such as hormonal suppression and predicted adult height instead.
Evidence assessment
Mixed evidence
DOWNGRADED FROM "strong" ON AUDIT. Histrelin is genuinely licensed and its registration trial is real and regulator-reviewed, but the evidence supporting it is far thinner than for leuprorelin or goserelin. There is no randomised controlled trial of histrelin at all. The pivotal study was a single-arm, open-label trial in 36 children with biochemical surrogate endpoints, and the only supporting publication is an observational cohort. That combination (approved labelling and reliable, mechanistically expected biochemical suppression, but zero randomised evidence and no hard clinical outcome data such as final adult height) is honestly described as mixed rather than strong. The delivery system, not the pharmacology, is what histrelin adds to the class; the underlying GnRH agonist mechanism is supported by the much larger evidence base of the class as a whole.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial Preclinical only
Peak stimulated LH and oestradiol were significantly suppressed by one month and suppression was maintained across 12 months. Growth velocity and bone age advancement slowed as expected. Implant-site reactions were the commonest adverse event and removal was sometimes difficult.
A single histrelin implant is effective for 2 years for treatment of central precocious puberty Preclinical only
A single implant maintained effective pubertal suppression for two years, suggesting annual replacement may be more frequent than necessary in some children. Not a randomised comparison of replacement intervals, so it has not changed licensed practice.
Safety
The systemic effects are those of the GnRH agonist class in children: an initial transient increase in pubertal signs during the flare phase, followed by suppression. Hot flushes, headache and mood change are reported. The distinctive risks are procedural rather than pharmacological. Implant-site reactions (bruising, pain, erythema and swelling) are the commonest adverse events. The implant is non-biodegradable and must be surgically removed; fibrous encapsulation can make removal difficult, and implant breakage during removal has been reported, occasionally requiring a further procedure to retrieve fragments. Spontaneous extrusion of the implant occurs rarely and would result in unrecognised loss of suppression. Effects on bone mineral density during treatment are a concern in a growing child, though density typically accrues normally once treatment stops and puberty resumes. In adult men formerly treated for prostate cancer with the lower-release adult implant, the standard androgen deprivation profile applied, including hot flushes, fatigue, loss of libido and bone loss, along with possible QT prolongation; that product has been discontinued.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Not held as a standard MHRA-licensed product; histrelin implants are not routinely available in the United Kingdom, where central precocious puberty is generally managed with licensed depot leuprorelin or triptorelin preparations. Any access would be via unlicensed import routes. |
| United States | Approved by the FDA. The currently marketed product is a 50 mg subdermal implant releasing approximately 65 micrograms of histrelin acetate per day over 12 months, licensed in 2007 for central precocious puberty in children. A separate, lower-release implant delivering approximately 50 micrograms per day was licensed in 2004 for palliative treatment of advanced prostate cancer but has since been discontinued and withdrawn from the United States market. CORRECTION ON AUDIT: the draft stated the paediatric implant releases 50 micrograms per day and described the prostate cancer implant as the higher dose. The current FDA labelling states the reverse. The paediatric implant is the higher-release product at approximately 65 micrograms per day. |
| WADA (sport) | Prohibited in male athletes at all times under section S2 of the WADA Prohibited List, which names histrelin among gonadotrophin-releasing hormone agonist analogues. Not prohibited in female athletes. |
Questions
Chiefly convenience and consistency. A single implant inserted under the skin of the inner upper arm releases drug at a near-constant rate for about a year, replacing repeated injections. For a child facing years of treatment, that means one minor procedure annually rather than twelve injections. The implant is also non-biodegradable, so it must be removed.
Weaker than most people assume for a licensed medicine. There has never been a randomised controlled trial of histrelin. Its registration rested on a single-arm, uncontrolled study of 36 children using hormonal suppression as the endpoint, supported by one observational cohort. The suppression it produces is real and reliable, and the class mechanism is very well established, but histrelin's own evidence base is thin and reports surrogate rather than clinical outcomes.
That is the licensed schedule, and it is what the registration trial tested. Independent published data suggest a single implant can maintain suppression for two years, but this comes from an observational cohort rather than a randomised comparison, so annual replacement remains standard.
The distinctive risks are procedural. Implant-site bruising, pain and swelling are common. Because the device is non-biodegradable and can become encapsulated in fibrous tissue, removal is occasionally difficult and the implant can break, sometimes requiring a further procedure to retrieve fragments. Rarely an implant extrudes spontaneously, which would silently end suppression.
The mechanism is sound (halting premature bone maturation preserves growth plate capacity), and it is the reason the treatment exists. But most trials, including the histrelin registration trial, report surrogate outcomes such as hormonal suppression, slowed bone age advancement and predicted adult height, because measuring true final height requires following children for a decade or more.